The Ethics of Derivatives and Risk Management

Ethical Perspectives 4 (2):84-93 (1997)
  Copy   BIBTEX

Abstract

The widespread and elaborate use of new financial instruments among corporate entities and financial institutions requires justification. It faces the charge of increasing both the level and complexity of risk in the financial system under the pretext of reducing it. It is a prodigious user of management resources and IT. It obscures the integrity of the nature of the non-financial user.It is not mere academic argument to question the ethics of certain instruments. Both in the US and the UK certain forms of financial instrument are deemed too risky to be used by all and sundry. Other forms of instrument may be banned outright, even though many financial professionals will be perfectly capable of measuring the risk involved. The force of this attack is recognized in the financial industry. One defence frequently put forward is similar to that of the National Rifle Association in the US about guns. It is the users, not the product, that are the problem. “One misconception is that derivatives are risky instruments that are used for speculation. It is more accurate to say that derivatives are instruments that can be used to alter risk profiles”. The mere fact of an instrument existing is no reason to use it. The biggest advocates of exotic options are bankers. Practising Treasurers spend much time seeking to distinguish between the fascinating idea which the bank’s rocket scientist wants to try, and the derivative that will genuinely benefit the company. The fact that many of these instruments are harmful or spurious does not mean they should be banned, but neither does the absence of a ban make them ethical.The ethical question to ask for the non-financial corporation has to do with the proper balance of courage and prudence. Will this instrument enable the company to carry out its proper task with more focus and self-awareness, or is it an attempt to neutralize the proper risks that we are paid to take? For financial corporations the inevitable presence of derivatives poses two issues. First, are they intrinsically valuable or simply so complicated that no client could use them and monitor the new exposures involved? Secondly, will the active management of our positions created by this activity result in a change in the nature of our business, and if so, has this been clearly communicated to the world around?On reading this again I am once more struck by a remark made to me by a clergyman long before I was ordained. “What is an ethical Treasurer?” One of the major challenges in the field of financial ethics is the development of an adequate, and clearly communicated, measure of the intrinsic ethics of finance.This paper is not arguing that derivatives are wrong, but that they are powerful, and power needs monitoring and controlling. The events of October 1987 are often referred to as the meltdown of the markets. My clear memory is of the whole executive board of directors standing in my office gazing in awe at a Topic Screen as waves of red chased across the screen. The use of nuclear metaphors was apt. A system that seemed safe had assumed a life of its own. There is little doubt that derivatives fuelled the reaction

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,386

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Risk Management as a Tool for Sustainability.Frank C. Krysiak - 2009 - Journal of Business Ethics 85 (S3):483 - 492.
Strategic reputation risk management.Judy Larkin - 2003 - New York: Palgrave-Macmillan.
Risk and Responsibility: A Complex and Evolving Relationship.Céline Kermisch - 2012 - Science and Engineering Ethics 18 (1):91-102.
Risk, uncertainty, and rational action.Carlo Jaeger (ed.) - 2001 - London: Earthscan.
Ethical risk management: guidelines for practice.William F. Doverspike - 1999 - Sarasota, Fla.: Professional Resource Press.
Prudent Precaution in Clinical Trials of Nanomedicines.Gary E. Marchant & Rachel A. Lindor - 2012 - Journal of Law, Medicine and Ethics 40 (4):831-840.
Antibiotic Resistance Due to Modern Agricultural Practices: An Ethical Perspective. [REVIEW]Joan Duckenfield - 2013 - Journal of Agricultural and Environmental Ethics 26 (2):333-350.

Analytics

Added to PP
2010-09-02

Downloads
68 (#235,492)

6 months
4 (#800,606)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references